Bevacizumab in Glaucoma: Where do We Stand?

The use of antivascular endothelial growth factors such as bevacizumab and ranibizumab has brought about a revolution in management protocols of various ophthalmic disorders. A lot has been written about these agents, still lacunae exist in our understanding due to paucity of randomized control tria...

Descripción completa

Detalles Bibliográficos
Autor principal: Khanna, Anjani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Jaypee Brothers Medical Publishers 2012
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161771/
https://www.ncbi.nlm.nih.gov/pubmed/28028350
http://dx.doi.org/10.5005/jp-journals-10008-1110
Descripción
Sumario:The use of antivascular endothelial growth factors such as bevacizumab and ranibizumab has brought about a revolution in management protocols of various ophthalmic disorders. A lot has been written about these agents, still lacunae exist in our understanding due to paucity of randomized control trials with large number of patients. This brief review attempts to throw light on the clinical applications of these molecules for glaucoma. HOW TO CITE THIS ARTICLE: Khanna A. Bevacizumab in Glaucoma: Where do We Stand? J Current Glau Prac 2012;6(2):75-78.

Ejemplares similares